Uptake of interferon‐free DAA therapy among HCV‐infected decompensated cirrhosis patients and evidence for decreased mortality

Abstract

Interferon‐free DAA therapies have recently been licensed for patients infected with hepatitis C virus (HCV) who have decompensated cirrhosis (DC). Our aim was to describe factors associated with uptake of IFN‐free DAAs in DC patients and to compare mortality risk and hospital admission rates between pre‐DAA and DAA eras. This observational study used record‐linkage between Scotland's HCV Clinical Database and national inpatient hospitalization and mortality registers. For the DAA uptake analysis, the study population (n = 297) was restricted to patients alive on 1 November 2014, and Cox regression was used to estimate uptake associated with various covariates. For the Cox regression of mortality comparing pre‐DAA and DAA eras, the study population (n = 624) comprised those diagnosed with DC in 2005–2018; follow‐up was censored at two years. DAA uptake was 63% overall and was significantly higher for treatment‐experienced patients (adjusted hazard ratio (aHR) = 1.64, 95% CI:1.14–2.34), genotype 1 vs. other genotypes (aHR = 1.55. 95% CI:1.15–2.10) and lower for persons diagnosed with DC pre‐2014 (0.47, 95% CI:0.33–0.68) and in Greater Glasgow (0.64, 95% CI:0.47–0.88). The intention‐to‐treat SVR rate was 89% (95% CI:83–93%). All‐cause and liver‐related mortality risk were significantly reduced among patients diagnosed with DC in the DAA era (November 2014–December 2018) compared with the pre‐DAA era (2005–October 2014) (aHRs of 0.68, 95% CI:0.49–0.93; 0.69, 95% CI:0.50–0.95, respectively); in contrast, hospital admission rates were higher in the DAA era (aRR = 1.14, 95% CI:1.04–1.26). The majority of HCV‐infected DC patients engaged with specialist services can be treated with IFN‐free DAAs. Improved survival among patients diagnosed with DC in the DAA era supports the beneficial impact of IFN‐free therapies among those with advanced liver disease.

Impact of simplified HCV diagnostic strategies on the HCV epidemic among men who have sex with men in the era of HIV oral pre‐exposure prophylaxis in Taiwan: a modelling study

“…Once HCV infected, individuals entered undiagnosed acute HCV infection and either spontaneously cleared the infection and became susceptible again (but HCV antibody positive) or developed chronic HCV infection but at a different rate based on their HIV infection status to reflect the impact of HCV disease progression by HIV/HCV coinfection [ 20 ]. MSM with advanced liver disease (decompensated cirrhosis, hepatocellular carcinoma, liver failure and requires treatment, and liver failure and received treatment) had additional HCV‐related liver mortality, and HCV‐related liver mortality was reduced when they attained HCV cure but still elevated compared to the susceptible population [ 21 , 22 , 23 ].…”

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

“…The selection of interferonfree DAA regimen depends on factors including HCV genotype/subtype, the presence or absence of cirrhosis, and prior treatment history. Some regimens cover all genotypes (pan-genotypic), and appropriate regimens and treatment duration are applicable to special populations including HCV and HIV co-infection [49], decompensated liver disease, HCV recurrence post-liver transplantation [50], and patients with advanced kidney disease [51]. Antiviral therapy can prevent clinical endpoints of CHC.…”

Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis

“…Recently developed DAAs are emerging as a new branch of standard HCV therapy that can significantly improve treatment outcomes [ 3 ]. Scott A McDonald et al [ 10 ].…”